The Boston-based biotechnology company Insilico Medicine announced this week that it will be presenting data from its first-in-human trial of a novel AI-designed drug – a pan-TEAD inhibitor known as ISM6331 – for patients with mesothelioma and other advanced solid tumors.
Insilico is a clinical-stage, generative AI-driven drug discovery company founded in 2011 that uses AI and machine learning to develop new medical treatments and design new drugs. Their latest project, aimed at the deadly cancer mesothelioma and other similar tumors, will be presented as a Rapid Oral presentation at the European Society for Medical Oncology (ESMO) Congress in Madrid, Spain in October.
“Presenting our first-in-human Phase 1 study at ESMO marks an important clinical milestone for ISM6331,” said Dr. Halle Zhang, Insilico’s Vice President, Clinical Development – Oncology. “Patients with advanced mesothelioma and other Hippo-driven solid tumors face limited therapeutic options. These preliminary clinical findings provide early encouragement as we evaluate ISM6331’s safety, pharmacokinetics, and initial antitumor activity to inform our ongoing clinical development strategies.”
The U.S. Food and Drug Administration (FDA) followed this announcement by granting ISM6331 a “fast-track” designation, which is meant to facilitate an expedited development and review and could lead to a much quicker approval and availability of the drug once it is ready for market.
What Is a Pan-TEAD Inhibitor?
According to Insilico, their new drug, ISM6331, is a class of medication known as a pan-TEAD inhibitor developed with its generative AI-powered drug discovery platform. The drug works within the Hippo signaling pathway, which is one of the biological processes through which cells in the human body interact with one another.
The Hippo signaling pathway is one of the key pathways through which the body regulates cell development, survival and therapeutic resistance within solid tumors. As such, the Hippo signaling pathway has been identified as a promising potential target for cancer drug development, although developing effective treatments in this area has to this point been a major challenge.
Insilico hopes to have made a breakthrough with its new pan-TEAD inhibitor. ISM6331 targets TEAD – short for transcriptional enhanced associate domain – proteins that are the primary effectors of the Hippo signaling pathway. Although these proteins had at one point been considered “undruggable,” Insilico will be presenting a pan-TEAD inhibitor that may be able to do just that.
How Is AI Used in Drug Development?
While the use of generative artificial intelligence has become part of many parts of modern life over the last few years, biotechnology companies have been using AI to aid in the discovery and development of new drugs for much longer.
Insilico is one of a number of firms that employ AI to help accelerate drug design timelines and identify which molecules are more likely to be effective in medical treatments. As the technology has become more sophisticated, AI has been used to help develop new classes of medicines.
ISM6331, Insilico’s pan-TEAD inhibitor, is a drug with a design process that has been led by generative AI. Insilico’s ESMO presentation will offer data on the drug’s “safety, tolerability, pharmacokinetics, and preliminary antitumor activity” in human subjects, and should provide next steps for its continued development in the treatment of mesothelioma and other cancers.
Sources & Author
- Insilico Medicine Announces Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of ISM6331 in Mesothelioma and Advanced Solid Tumors. Insilico Medicine. Retrieved from https://insilico.com/news/hch8g6ih51-insilico-medicine-announces-oral-present?amp=true. Accessed 07/29/2026.
- Something to YAP About! Progress Targeting YAP/TAZ-TEAD Signaling in Cancer Research. Cell Signaling Technology. Retrieved from https://blog.cellsignal.com/small-molecule-yap-taz-tead-signaling. Accessed 07/29/2026.
- Cooperation between the Hippo and MAPK pathway activation drives acquired resistance to TEAD inhibition. Nature Communications. Retrieved from https://www.nature.com/articles/s41467-025-56634-y. Accessed 07/29/2026.
- How AI helps scientists design the next generation of medicines. MIT Technology Review. Retrieved from https://www.technologyreview.com/2026/07/23/1140346/how-ai-helps-scientists-design-the-next-generation-of-medicines/. Accessed 07/29/2026.
- FDA Grants Fast Track Designation to ISM6331 for Advanced Mesothelioma. Targeted Oncology. Retrieved from https://www.targetedonc.com/view/fda-grants-fast-track-designation-to-ism6331-for-advanced-mesothelioma. Accessed 07/30/2026.
